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that chymase is important for progression of the disease and suggests that pharmacological blockade of chymase may provide beneficial effects. The current studies were performed in the db/db mouse (BKS.Cg-Dock7 m +/+ Lepr db /J), which is an animal model of type 2 diabetes mellitus exhibiting features of human DN. [19] [20] [21] Our previous study, 22 as well as those of the research group of Batlle et al, [23] [24] [25] have demonstrated a significant decrease in ACE protein expression and activity in the diabetic db/db compared with the control db/m kidney. Plasma and kidney ANGII levels were similar in db/db and db/m mice suggesting an augmentation of alternative ANGII forming enzymatic pathways in the db/db mice. 22 In spite of reduced ACE activity, afferent arterioles (AA) of control and diabetic kidneys responded with a similar magnitude of vasoconstriction to the intrarenal conversion of bath applied ANGI to ANGII. 22 In kidneys of control mice, AA vasoconstrictor responses were mediated by ACE-dependent conversion of ANGI to ANGII; in contrast, AA vasoconstrictor responses in diabetic mice were mediated by serine protease-dependent conversion of ANGI to ANGII. 22 The rationale for conducting the current studies was to provide direct evidence for chymase as the specific serine protease responsible for ANGII formation in diabetic renal vascular disease.
We tested the hypothesis that there is a switch from renal ACE-dependent to chymase-dependent ANGII formation in diabetic vascular disease. Renal AA vascular responses to the intrarenal enzymatic conversion of ACE-specific and chymase-specific ANGI analogs to ANGII were determined in the absence or presence of a chymase inhibitor to determine the specific serine protease-dependent enzyme responsible for the intrarenal conversion of ANGI to ANGII in normal and diabetic kidneys. Quantification of vascular ACE and chymase mRNA expression was performed to provide support for the determination of the predominant intrarenal ANGII forming enzymes on vascular function in the type 2 diabetic kidney.
Methods
An extended Methods section is available in the online-only Data Supplement. 
Animals

Mouse In Vitro Blood Perfused Juxtamedullary Nephron Technique
Experiments were conducted using the mouse in vitro blood perfused juxtamedullary nephron technique as we have previously reported in detail. 22, 26, 27 AA diameters were measured during the following protocols:
ACE-specific, chymase-resistant ANGI ([Pro
10
]ANGI) peptide (Table) ]ANGI in the presence of chymasespecific inhibitor in diabetic mice (n=3). 5. ANGI in the presence of chymase inhibition. Kidneys of diabetic (n=6) and control (n=6) mice were exposed to human ANGI in the continued presence of chymase inhibition.
Quantitative Assessment of Renal Arterial Vascular Tissues
The renal arterial vasculature was isolated from diabetic and control mice as described by Schneider et al, 30 and Western blot 31 and realtime-polymerase chain reaction 32 were performed on the tissues.
Data Analyses and Statistics
AA luminal diameters were measured manually and continuously using a digital image-shearing monitor. 22, 26, 27 One-way repeated-measures ANOVA, 2-way ANOVA followed by Dunnett or Bonferroni test, paired t test, or unpaired t test were used as appropriate. P≤0.05 was considered statistically significant. Values are means±SEM. 
Results
Baseline Parameters
Body weight was significantly higher in 18-week-old adult male diabetic (48.7±0.07 g; n=38) compared with control (32.2±0.04 g; n=38) mouse littermates. Baseline AA diameters of kidneys from diabetic mice (14.6±0.5 μm; n=31) were significantly larger than AAs from control (13.0±0.5 μm; n=27) mice.
AA Vasoconstrictor Responses to ACE-Specific [Pro
10
]ANGI Figure 1 demonstrates the AA vasoconstriction to the ACEspecific, chymase-resistant ANGI peptide ([Pro 10 ]ANGI; 0-1000 nmol/L). Figure 1A illustrates the average AA responses plotted in microns, and Figure 1B Figure 3 illustrates the average AA responses to ANGI in the presence of chymase inhibition plotted in microns ( Figure 3A ) and delta % of baseline ( Figure 3B ) in kidneys from control and diabetic mice. In the presence of chymase inhibition, significant AA vasoconstriction to 10, 100, 1000 nmol/L ANGI (−12±2, −19±4, −30±3%; n=6) was observed in kidneys of control mice. However, chymase inhibition significantly attenuated the AA vasoconstriction to 10, 100, 1000 nmol/L ANGI (−7±4, −9±3, −11±4%; n=6) in kidneys of diabetic mice. In the presence of chymase inhibition, ANGI produced ]ANGI (P<0.05), whereas arterioles from diabetic mice did not respond. There was a significant difference between the AA diameter responses of diabetic and control kidneys. *P≤0.05 vs baseline diameter; †P≤0.05 control vs diabetic. a significantly greater response in AAs from control compared with diabetic mice. At the conclusion of protocols 1 and 2, AA contractile responsiveness to ANGI remained intact in control (−12±2%; n=11) and diabetic (−11±1%; n=10) kidneys ( Figure S1A in the online-only Data Supplement). In the continued presence of AT 1 receptor blockade, norepinephrine produced a rapid and significant vasoconstriction in AAs of control and diabetic kidneys (−46±4, −35±6%; n=5, 7, respectively; Figure  S1B ). AA contractile responsiveness to ANGII remained intact in control (−24±2%; n=10) and diabetic (−18±2%; n=9) kidneys at the conclusion of protocols 2 and 5 ( Figure  S1C ). The magnitude of the AA vasoconstrictions produced by ANGI, norepinephrine, and ANGII were not significantly different between kidneys of control and diabetic mice ( Figure S1 ).
AA Responses to ANGI in the Presence of Chymase Blockade
Quantitative Assessment of Renal Arterial Vascular Tissues
The renal vascular tissue isolation procedure yielded a significant 14.2±0.5-fold enrichment of α-smooth muscle actin (α-SMA) protein expression compared with renal cortical tissues from control mice ( Figure 4A and 4B) . Renal cortical tissue ACE protein expression was 16.5±0.7-fold enriched compared with renal vascular tissues from control mice ( Figure  4C and 4D) . Renal vascular tissues isolated from diabetic mice expressed significantly augmented mouse mast cell protease-4 (chymase) mRNA expression of 5.1±1.4-fold ( Figure 4E ) and attenuated ACE mRNA expression of 0.42±0.08 fold ( Figure 4F ) compared with control mice.
Discussion
Current drug therapies for the treatment of diabetic renal disease may slow the progression of the damage, but do not stop disease progression or restore normal kidney function for these patients. Despite the widespread use of inhibitors of the renin-angiotensin system and glucose-lowering medications, the incidence of diabetes-related end-stage renal disease continues to rise steadily indicating the need for the continued search for the mechanisms involved in the development and progression of DN.
Chymase has received considerable attention as an ACEindependent means to produce ANGII. It has been shown that the formation of ANGII from ANGI in coronary arteries 33 and kidney microvessels 22, 34, 35 is dependent on both ACE (captopril inhibitable) and ACE-independent (chymostatin inhibitable) pathways. Our published work 22 indicates that AA vasoconstriction produced by the intrarenal conversion of ANGI to ANGII is of similar magnitude in diabetic and control kidneys. Inhibition of microvascular responses to intrarenal conversion of ANGI to ANGII by captopril indicated that ACE is the predominant pathway for ANGII formation in the normal mouse kidney. In contrast, in diabetic kidneys, AA vasoconstriction produced by the intrarenal conversion of ANGI to ANGII was not attenuated by ACE inhibition, but was significantly attenuated by serine protease inhibition. Our earlier studies used ACE and nonspecific serine protease inhibitors as a means to determine the major enzymatic pathways for intrarenal conversion of exogenously applied ANGI. Sequences for the synthesis of ANGI peptide analogs were obtained from the work of Husain et al. 28, 36 The ANGI analogs contain specific amino acid sequences that make them substrate-specific for either ACE or chymase enzymatic activity that allowed for the quantitative assessment of renal microvascular functional responses to the intrarenal conversion of these analogs to ANGII. ANGII synthesized via ACE and chymase-dependent pathways within the renal endothelium, microvasculature, glomerulus, tubules, and interstitium may act in an autocrine/paracrine manner via binding to plasma membrane AT 1 receptors located on AA vascular smooth muscle cells.
The efficiency of human heart chymase for peptides with proline in the P 2 ʹ position of ANGI is decreased by 95% compared with ANGI, 37 indicating that this analog is chymaseresistant. Furthermore, the positive inotropic response of [Pro 10 ]ANGI on hamster papillary muscle was completely suppressed by captopril pretreatment, 36 indicating that the analog is specific for ACE. In our study, AA vasoconstriction to the ACE-specific, chymase-resistant [Pro 10 ]ANGI was significantly greater in control than diabetic mice confirming significantly reduced ACE activity in the diabetic kidney. The significant AA responses to the ACE-specific, chymase-resistant ANGI analog confirm our previous work 22 demonstrating that ACE is the predominant ANGII forming enzyme in the normal kidney.
It is well known that peptides with a proline in the penultimate position prevent ACE from cleaving a dipeptide from the carboxy terminus. The addition of a carboxy-terminal D-Ala prevents carboxypeptidases from making the penultimate proline into a carboxy-terminal proline. Hoit et al 38 ]ANGI were not impacted by ACE inhibition in the conscious baboon and mouse. 28 Additionally, the control kidney has minimal chymase activity. A significantly greater chymase and reduced ACE mRNA expression was detected in the renal vasculature of diabetic compared with control mice. The renal vascular isolation technique yielded an enhanced α-smooth muscle actin and diminished ACE protein expression compared with cortical tissues demonstrating a significant enrichment of vascular tissue and minimal tubular tissue in the protein and RNA extracts. These data are consistent with the microvascular physiological functional studies for intrarenal ANGII formation and support our hypothesis that there is a switch from ACE-dependent to chymase-dependent activity in the diabetic kidney.
Our previous work demonstrated a significant reduction in the density of renal cortical tubular ACE immunohistochemical staining and cortical ACE activity in diabetic compared with control mice 22 , which is consistent with the work of Ye et al. 23 In further studies, Ye et al 24 reported that the percentage of glomeruli with strong endothelial ACE staining was significantly greater in 8-week-old female db/db mice compared with control mice, which conflicts with our functional data in 18-week-old male db/db mice. Of interest are the findings of Soler et al 39 in which the percent of renal vessels demonstrating strong endothelial ACE immunostaining was increased in streptozotocin-induced type 1 diabetic compared with control mice. It is not clear whether the age, sex, or type of diabetic model influences renal arterial endothelial ACE protein expression.
The vasoconstrictor responses to conversion of [Pro ] to ANGII are attributed to intrarenal chymase activity because these responses were blocked by the chymase inhibitor. These data implicate the importance of chymase as the primary route of formation of ANGII from ANGI in diabetic kidneys.
Most importantly, key data suggest that the AA vasoconstriction induced by intrarenal conversion of the endogenous form of ANGI to ANGII is significantly attenuated by a specific chymase inhibitor in kidneys of diabetic mice, but not in kidneys of control mice. The potent phosphinate chymase inhibitor, JNJ-18054478, complexes with mammalian chymases and exhibits a potency of ≈0.07 μmol/L against human and macaque chymases and 5 μmol/L for guinea pig and hamster chymases. 40 The 10μmol/L dose of the chymase inhibitor, JNJ-18054478, produced a complete inhibition of the AA vasoconstriction produced by intrarenal conversion of the chymase-specific, ACE-resistant [Pro control kidneys provides support for the significant differences observed between AAs from diabetic and control kidneys in response to the enzyme-specific ANGI analogs. The magnitude of the AA vasoconstriction of the diabetic kidney to 1 μmol/L [Pro 11 , D-Ala 12 ]ANGI (−24±3%) was very similar to the magnitude of the vasoconstriction of the control kidney in response to 1 μmol/L ANGI in the presence of chymase inhibition (−30±3%). These data suggest that there is a similar magnitude of ANGII formation by chymasedependent and ACE-dependent pathways in diabetic and control kidneys, respectively. Recent studies have shown that chymase inhibition protects against renal dysfunction in type 1 diabetic hamsters. 41 In addition, chymase (mouse mast cell protease-4) deficient mice exhibit lower proteinuria, blood creatinine, and urea nitrogen levels, and less severe renal damage compared with wild-type mice indicating an aggravating role of renal chymase in glomerulonephritis disease progression. 42 The most significant finding of the present study is the identification of chymase as the major ACE-independent pathway for the formation of ANGII in the type 2 diabetic leptin-receptor deficient mouse kidney. In the diabetic kidney, AA vasoconstriction to intrarenally formed ANGII from the substrate ANGI is blocked by inhibition of chymase activity. In contrast, intrarenally formed ANGII from the substrate ANGI produces a potent AA vasoconstriction in the presence of chymase inhibition in the control kidney. Our studies may provide a potential mechanism involved in the superior renoprotective effects of combining an ACE inhibitor with an AT 1 receptor antagonist relative to ACE inhibitor therapy alone in patients with DN, which has been reported in some clinical studies. 43, 44 In addition, the presence of this ACE-independent pathway for ANGII formation may explain the continued proteinuria in some patients on maximal ACE inhibitor therapy. 45 However, the ONTARGET trial indicated that in patients with cardiovascular disease or diabetes mellitus, the combination of ANG receptor blocker and ACE inhibitor provided more adverse events without an increase in benefit compared with either monotherapy. 46 We suggest that ACE inhibitor monotherapy may allow for the continued generation of ANGII via chymase-dependent pathways, which contributes to fibrosis, proteinuria, and reduced renal function in diabetic patients.
Perspectives
Despite the first-line use of ACE inhibitors and ANG receptor blockers for the treatment of DN, there is still a large need to improve therapies for the prevention of DN and dramatically reduce the rates of disease progression for these patients. Our studies support a major role for chymase-dependent ANGII formation in the db/db renal vasculature and thus provide a novel translational approach to human disease. Chymase inhibition may provide substantial renal protection in diabetic patients. Physicians may treat with an ANG receptor blocker when diabetic renal disease patients are unresponsive to ACE inhibition. Treatment with an ANG receptor blocker may provide additional benefit because of the inhibition of ANGII produced by ACE-dependent and chymase-dependent pathways. Targeting chymase as a therapeutic target for chronic kidney disease patients with normal blood pressure may provide the advantage of reducing intrarenal chymase-dependent fibrosis, proteinuria, and vasoconstriction without causing systemic hypotension that can lead to further reductions in glomerular filtration rate and renal blood flow, which is often observed with treatment with ACE inhibitors or ANG receptor blockers. ANGI or ANGI in the presence of the chymase-specific inhibitor, JNJ-18054478 in kidneys from control ( ) and diabetic ( ) mice. There were no significant differences in the magnitude of the AA vasoconstrictor responses to ANGI, NE, or ANGII in control compared to diabetic mice. * p≤0.05 vs. recovery diameter
